Alps Advisors Inc. Acquires New Shares in Royalty Pharma PLC $RPRX

Alps Advisors Inc. acquired a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 553,124 shares of the biopharmaceutical company’s stock, valued at approximately $19,514,000. Alps Advisors Inc. owned about 0.09% of Royalty Pharma as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of RPRX. MMA Asset Management LLC raised its stake in shares of Royalty Pharma by 56.1% during the 3rd quarter. MMA Asset Management LLC now owns 13,809 shares of the biopharmaceutical company’s stock worth $487,000 after buying an additional 4,960 shares during the last quarter. C WorldWide Group Holding A S increased its holdings in Royalty Pharma by 4.3% during the 3rd quarter. C WorldWide Group Holding A S now owns 654,457 shares of the biopharmaceutical company’s stock valued at $23,089,000 after acquiring an additional 27,089 shares in the last quarter. ABN AMRO Bank N.V. raised its position in Royalty Pharma by 12.5% during the third quarter. ABN AMRO Bank N.V. now owns 38,700 shares of the biopharmaceutical company’s stock worth $1,361,000 after acquiring an additional 4,306 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of Royalty Pharma in the third quarter valued at about $218,000. Finally, Savant Capital LLC lifted its holdings in shares of Royalty Pharma by 7.2% in the third quarter. Savant Capital LLC now owns 7,591 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 509 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Insider Transactions at Royalty Pharma

In related news, CFO Terrance P. Coyne sold 114,954 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $42.84, for a total transaction of $4,924,629.36. Following the completion of the transaction, the chief financial officer owned 23,972 shares of the company’s stock, valued at approximately $1,026,960.48. This represents a 82.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP George W. Lloyd sold 132,426 shares of Royalty Pharma stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $38.34, for a total transaction of $5,077,212.84. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 1,309,216 shares of company stock valued at $52,015,364. Corporate insiders own 18.90% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on RPRX shares. UBS Group raised shares of Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price objective for the company in a research note on Friday, January 30th. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, December 11th. Leerink Partners set a $45.00 price objective on Royalty Pharma in a research note on Thursday, December 11th. Finally, Citigroup boosted their target price on shares of Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.50.

Royalty Pharma Price Performance

RPRX stock opened at $44.65 on Monday. The stock has a market capitalization of $25.77 billion, a price-to-earnings ratio of 33.83, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. The company has a quick ratio of 3.48, a current ratio of 3.48 and a debt-to-equity ratio of 0.89. Royalty Pharma PLC has a 52-week low of $29.66 and a 52-week high of $44.93. The stock’s fifty day simple moving average is $39.91 and its 200-day simple moving average is $38.02.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be issued a $0.235 dividend. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date is Friday, February 20th. This represents a $0.94 annualized dividend and a yield of 2.1%. Royalty Pharma’s dividend payout ratio (DPR) is presently 71.21%.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.